Trial Profile
A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2021
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary)
- Indications Breast cancer; Cancer; Liposarcoma; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma
- Focus Pharmacokinetics
- Sponsors Novartis
- 08 Feb 2021 Results published in the Journal of Clinical Pharmacology
- 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 13 Feb 2017 Status changed from recruiting to completed.